Stacey L. Berg, MD
Department or Service
- Texas Medical Center
Director, Palliative Care Program
Director, Developmental Therapeutics Program
Professor, Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine
|NIH/NIAID||fellowship||Pediatric Hematology Oncology||1994|
|University of Pittsburgh School of Medicine||residency||Pediatrics||1988|
|University of Pittsburgh School of Medicine||internship||Pediatrics||1986|
|University of Pittsburgh School of Medicine||medical school||Doctor of Medicine||1985|
Dr. Stacey Berg is the Director of both the Developmental Therapeutics Program and the Palliative Care Program at Texas Children's Cancer and Hematology Centers. Dr. Stacey Berg's primary area of interest is pharmacology and experimental therapeutics, with a special emphasis on the development of new anticancer drugs for children. Her clinical interests include: pharmacology, new drug development, and hospice and palliative care.
|American Academy of Hospice and Palliative Medicine||Member|
|American Academy of Pediatrics (AAP)||Member|
|American Association for Cancer Research (AACR)||Member|
|American Society Clinical Oncology (ASCO)||Member|
|Children's Oncology Group (COG)||Developmental Therapeutics Steering Committee|
In addition to these, Dr. Stacey Berg also has a strong interest in clinical trial design, biomedical ethics, and the incorporation of palliative care principles into pediatric oncology practice.
In the laboratory, Dr. Berg's interests include preclinical investigation of the pharmacokinetics of new agents. Drug concentrations are determined by high-pressure liquid chromatography or other appropriate methods. Data are analyzed with a variety of computer modeling strategies. These data facilitate the development of new therapies of children with cancer.